Article

Happiness and Medicine

John D. Kelly, IV, MD, Vice Chairman/Director, Sports Medicine/Orthopaedics, Temple University School of Medicine, discusses the importance of happiness in medicine.

John D. Kelly, IV, MD, Vice Chairman/Director, Sports Medicine/Orthopaedics, Temple University School of Medicine, discusses the importance of happiness in medicine.

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
MeiLan Han, MD: Discussing Updates on Dupilumab, Ensifentrine in 2025 GOLD Report
Related Content
Ankeet Bhatt, MD, MBA, ScM | Credit: American Heart Association
November 17th 2024

Understanding NUDGLE-FLU Data from AHA 2024, with Ankeet Bhatt, MD, MBA, ScM

Ankeet Bhatt, MD, MBA Patrick Campbell
Kidney Compass: Atacicept for IgAN with Jonathan Barratt, MD, PhD, at Kidney Week 2024
October 27th 2024

Kidney Compass: Atacicept for IgAN with Jonathan Barratt, MD, PhD, at Kidney Week 2024

Brendon Neuen, MBBS, PhD Shikha Wadhwani, MD, MS
Hallucinogen-Related ER Visit Linked to Increased Schizophrenia Risk
November 14th 2024

Hallucinogen-Related ER Visit Linked to Increased Schizophrenia Risk

Chelsie Derman
Default thumbnail for Medical Ethics Unpacked
October 17th 2024

Introducing Medical Ethics Unpacked, with Dominic Sisti, PhD, and Steve Levine, MD

Steve Levine, MD Dominic Sisti, PhD
Ellen Sher, MD | Credit: Allergy Partners
November 11th 2024

Ellen Sher, MD: Cross-Specialty Collaboration Can Improve Atopic Dermatitis Management

Ellen Sher, MD Patrick Campbell
Emraclidine Fails to Significantly Reduce Schizophrenia Symptoms in Phase 2 EMPOWER Trials
November 11th 2024

Emraclidine Fails to Significantly Reduce Schizophrenia Symptoms in Phase 2 EMPOWER Trials

Chelsie Derman
© 2024 MJH Life Sciences

All rights reserved.